

WHEN LIFE  
PUTS A  
FULL STOP. ●

WE ADD TWO MORE,  
SO THAT HOPE  
CONTINUES TO WIN ●●●

That's exactly why we double hope by doubling your contribution\*



RISE AGAINST CANCER

## HDFC Charity Fund for Cancer Cure

(A Fixed Maturity Plan)

**#InvestInOthers**

**NFO  
Period:**

28<sup>th</sup> July to  
8<sup>th</sup> August  
2023

To know more contact your MFD/RIA or give a missed call on 73974 12345

\*HDFC AMC shall contribute to Indian Cancer Society an amount equivalent to the total amount of Donations by the Donors, in such financial year, under the Scheme, subject to a limit of ₹16 Crores per financial year.

For product labelling & riskometer refer slide 17

# Series of Cancer Cure Funds to help underprivileged cancer patients with support of Indian Cancer Society

- ✓ First scheme - HDFC Debt Fund for Cancer Cure launched in 2011 to commemorate 10 years of establishing HDFC Mutual Fund. HDFC Debt Fund for Cancer Cure (2011) matured in 2014
- ✓ Second Scheme HDFC Debt Fund for Cancer Cure was launched in 2014 and matured in 2017
- ✓ Third Scheme HDFC Charity Fund for Cancer Cure was launched in 2017 and matured in 2020
- ✓ Unique Scheme, aims at generating stable cash flows for a deserving cause
- ✓ Aims to take care of philanthropic needs
- ✓ Money raised through donation of IDCW (Income Distribution cum Capital Withdrawal) by investors to be utilized by the Indian Cancer Society (ICS) for treatment of underprivileged cancer patients





# Series of Cancer Cure Funds – Contribution

Details of the first three launches are as under:

Scheme Name	Year of Inception	Corpus Collected	Total Contribution to ICS under the initiative
HDFC Debt Fund for Cancer Cure	2011	₹77 cr	₹12.77 cr
HDFC Debt Fund for Cancer Cure 2014	2014	₹175 cr	₹25.87 cr
HDFC Charity Fund for Cancer Cure	2017	₹308 cr	₹45.55 cr
HDFC AMC's Direct Contribution (2013*-23)			₹105.52 cr
<b>Total</b>			<b>₹189.71 cr</b>

As a commitment to the cause, HDFC AMC has waived all charges towards Investment & Management Fees under the series

**Over the tenure of series - total contribution made ₹ 189.71 cr**

\* The year that HDFC AMC has started contributing  
For disclaimer refer slide 18

# Series of Cancer Cure Funds – Impacting lives

An initiative with “different” track record


<b>Number of hospitals empanelled</b>	<b>19</b>
Amount Sanctioned	₹268.53 cr*
Amount Disbursed	₹226.13 cr*
Number of Patients Funded under the initiative	13070

**Impacted over 13K lives  
between 2011-23**


\*Includes contributions from other institutions and individuals

## Demographics of Beneficiaries


**Age Wise Classification**



**Gender wise classification**



**Diagnosis wise classification**




Data as on March 31, 2023  
Source: Indian Cancer Society

For disclaimer refer slide 18

# Cure Map – Spread Across India

Sr.No	Hospital	Supported Beneficiaries
1	Tata Memorial Hospital, Mumbai, Maharashtra (TMH)	3140
2	Christian Medical College, Vellore, Tamil Nadu (CMC)	1680
3	Cancer Institute, Adyar, Tamil Nadu (CI)	1345
4	Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, Telangana (INDO-AMR)	1127
5	Kailash Cancer Hospital and Research Centre, Goraj, Gujarat (KCH)	1039
6	Regional Cancer Centre, Trivandrum, Kerala (RCC)	814
7	Sri Shankara Cancer Hospital And Research Centre, Bangalore, Karnataka (SSCHRC)	683
8	Mahavir Cancer Centre and Research Centre, Patna, Bihar (MCSRC)	538
9	Rajiv Gandhi Cancer and Research Institute, Delhi, Delhi (RGCI)	454
10	Sher-I-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir (SKIMS)	417
11	BKL Walawalkar Hospital, Chiplun, Maharashtra (BKL)	311
12	Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh (HBCH)	302
13	Cachar Cancer Hospital and Research Centre, Silchar, Assam (CCHRC)	264
14	Gujarat Cancer and Research Institute, Ahmedabad, Gujarat (GCRI)	241
15	Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh (MPMMMCC - Varanasi)	214
16	Patel Hospital, Jalandhar, Punjab (PATEL)	187
17	Tata Medical Centre, Kolkata, West Bengal (TMC)*	178
18	Balco Medical Centre, Raipur, Chhattisgarh (BMC)	47
19	Padhar Hopsital, Betul, Madhya Pradesh (PH)	40
20	Birla Cancer Centre And SMS Medical College Hospital, Jaipur, Rajasthan (SMS)*	28
21	Mazumdar Shaw Cancer Centre, Bangalore, Karnataka (MSMC) *	21
22	Chittranjan National Cancer Institute, Kolkata, West Bengal	
	<b>Grand Total</b>	<b>13070</b>




\* Dis-empanelled

Source: Indian Cancer Society

Note: This map is for pictorial representation purpose only and with no depiction of boundaries as approved by Government of India

**19 hospitals helping patients across 28 states and 8 Union Territories**

# How donation is utilized through ICS – CCF?



ICS - CCF - Indian Cancer Society - Cancer Cure Fund, Source: Indian Cancer Society

\*NAVYA AI – a clinically validated AI system – matches clinical data of beneficiary applicants with evidence and expert recommendation, adapted to ICS-CCF approval criteria.  
AI & DDT members are volunteers & ICS - CCF Team are members of ICS



Mrs Usha Thorat (Chairperson) (Former Deputy Governor, RBI)	Dr. Shailesh Ayyangar (Former MD, Sanofi India)
Mr M K Sharma (Former Vice Chairman of Hindustan Unilever)	Mr. Ramesh Swaminathan (Ex Director & CFO, Lupin Pharma)
Mr Navneet Munot (MD and CEO, HDFC AMC Ltd.)	Mrs. Jyotsna Govil (Head, ICS-Delhi Branch)
Dr. Anita Borges (Director Centre for Oncopathology)	Mr. Kishore Rao (Head, ICS-Mumbai Branch)
Mr. Uday Khanna (Former Chairman Bata India Ltd.)	Mr. Gautam Chakravarti (CEO Gokaldas Exports)
Mr. Naveen Kshatriya (Former MD Castrol India & Head of Castrol Asia)	Dr. Purna Kurkure (Medical Director, Section Head, SRCC Children’s Hospital)
Mr. Hari L Mundra (Former ED Hindustan Unilever)	Mr. Kewal Nohria (Former Chairman and MD, Crompton Greaves)
Dr. Manju Sengar (Prof. Adult Hematolymphoid, TMC)	Dr. Nilesh M Lokeshwar (Consultant – Medical Oncologist)

## Role of GAC Members

- ✓ Approve financial assistance to applicants
- ✓ Approve guidelines for utilization and disbursement of funds
- ✓ Conduct periodic reviews on the performance of the department and the cases approved for cancer treatment aid
- ✓ Appoint auditors for audit of ICS-CCF and its utilization

Data as on June 30, 2023  
Source: Indian Cancer Society

For disclaimer refer slide 18

# Who is eligible, for what purpose and how much?



## Patient's eligibility criteria

- ✓ Indian Citizen
- ✓ Underprivileged cancer patients



## What the support covers

- ✓ Surgery
- ✓ Chemotherapy
- ✓ Radiation Therapy
- ✓ Supportive Care (Investigation charges including all the tests)
- ✓ Prosthesis



## How much

- ✓ Upto ₹5 Lakh\* per patient and for Bone Marrow Transplant upto ₹8 Lakh\*

Source: Indian Cancer Society  
\*which may be reviewed from time to time

For disclaimer refer slide 18



**Indian Cancer Society was established in 1951 by Dr. D.J. Jussawalla and Mr. Naval Tata as India's first voluntary, non-profit, National Organization for Awareness, Detection, Cure and Survivorship of those affected with this disease.**




## Activities of ICS

- ✓ Creating nationwide awareness of cancer, its risk factors, preventive measures, encouraging regular checkups, treatment options and survivorship
- ✓ Providing for early detection of cancer through cancer detection centers and mobile cancer detection camps across India, especially for the underprivileged
- ✓ Providing funds for the treatment of cancer for poor cancer patients across India
- ✓ Providing support during and after treatment to poor cancer patients through rehabilitation, and survivor support groups
- ✓ Gathering and collating data through the population based cancer registry for Mumbai, Pune, Nagpur and Aurangabad (ICS is the only NGO to run a cancer registry), and providing analytic and projected reports on the incidence of cancer
- ✓ Providing a medium for the dissemination of information and research findings to the medical fraternity through the Indian Journal of Cancer

*Presenting*  
**HDFC Charity Fund  
for Cancer Cure**  
(A Fixed Maturity Plan)

NFO Opens on : 28<sup>th</sup> July 2023  
NFO Closes on : 8<sup>th</sup> August 2023



# Why should you invest in HDFC Charity Fund for Cancer Cure (A Fixed Maturity Plan) ?

- ✓ Unique Mutual Fund Scheme that allows you to contribute towards a visible cause
- ✓ The Scheme allows you to combine investments along with philanthropy
- ✓ The Scheme enables investors to donate part of distribution income to Indian Cancer Society for treatment of underprivileged cancer patients
- ✓ Choice 50% and 75% of IDCW distribution as donation




In view of individual nature of tax consequences, each unit holder is advised to consult their own professional tax advisors.

For disclaimer refer slide 18



# How does the Scheme Work?




**Donations to ICS contributed via IDCW may qualify for corporate investors' Corporate Social Responsibility (CSR) subject to their respective CSR agenda/policy, for which investors need to get in touch with ICS directly.**

**Donation of income to ICS is eligible for claiming of deduction U/S 80 G of Income Tax Act, 1961 under old regime**

Upon receipt of donations the Indian Cancer Society will issue 80G certificates to investors based on their respective donations.  
For disclaimer refer slide 18

# 2x Impact – Enhancement by HDFC AMC



\*Subject to limit of ₹16 crores per financial year  
Investors have an option to donate either 50% or 75% of IDCW distributed.

For disclaimer refer slide 18

<b>Name of the Scheme</b>	<b>HDFC Charity Fund for Cancer Cure (A Fixed Maturity Plan)</b>
<b>Type of Scheme</b>	A Close Ended Income Scheme With Tenure 1196 Days. A Relatively High Interest Rate Risk and Relatively Low Credit Risk.
<b>Investment Objective</b>	To generate income through investments in Debt / Money Market Instruments and Government Securities maturing on or before the maturity date of the Scheme. <b>There is no assurance that the investment objective of the Scheme will be realized.</b>
<b>Purpose of the Scheme</b>	The Scheme enables its Unit holders to donate part of distribution income to the Indian Cancer Society for treatment of underprivileged cancer patients. Such donations made by the Unit holders shall be eligible for claiming of deduction under Section 80G of Income-tax Act, 1961 (under the Old Regime).
<b>Benchmark Index</b>	Nifty Medium Duration Debt Index
<b>Fund Manager</b>	Mr. Anil Bamboli and Mr. Dhruv Muchhal (dedicated Fund Manager for overseas Investments)
<b>Investment Plans</b>	• Direct Plan • Regular Plan Since all distribution expenses / commission shall be borne by the AMC, there shall be no difference between the expenses / TER charged to Direct Plan and to Regular Plan
<b>Investment Options</b>	Under Each Plan only Payout of Income Distribution cum Capital Withdrawal (IDCW) Option with the following sub - options: • 50% IDCW Donation Option • 75% IDCW Donation Option
<b>Minimum Application Amount</b>	<b>During NFO Period</b> <b>Purchase:</b> ₹50,000/- and in multiples of ₹1,000/- thereafter per application Note: Allotment of units will be done after deduction of applicable stamp duty and transaction charges, if any.
<b>Load Structure</b>	<b>Entry Load: Not Applicable.</b> Pursuant to SEBI Circular No. SEBI/IMD/CIR No.4/168230/09 dated June 30, 2009, no entry load will be charged by the Scheme to the investor. <b>Exit Load:</b> • NIL
<b>Investment Management and Advisory Fee</b>	NIL. This Scheme being a philanthropic initiative by the AMC, no investment management and advisory fee shall be charged by the AMC to the scheme

For further details, refer Scheme Information Document (SID) and Key Information Memorandum (KIM) available on [www.hdfcfund.com](http://www.hdfcfund.com) and at Investor Service Centres of HDFC Mutual Fund

For disclaimer refer slide 18



Under normal circumstances, the asset allocation of the scheme's portfolio will be as follows:

Types of Instruments*	Minimum Allocation (% of Net Assets)	Maximum Allocation (% of Net Assets)	Risk Profile
Debt Instruments@, Money Market Instruments and Government Securities	0	100	Medium

\*Including securitized debt, structured obligations (SO), credit enhanced debt (CE). Investment in Securitized debt if undertaken, would not exceed 40% of the net assets of the Scheme.

@ Includes CDs issued by All-India Financial Institutions permitted by RBI from time to time

The Scheme may invest up to 35% of its net assets in foreign securities maturing on or before the maturity date of the Scheme.

# Intended Portfolio Allocation

The Scheme will invest in securities with floors and ceiling within a range of 5% of the intended allocation against each sub class of asset as indicated below in accordance with clause 13.6.2.4 of SEBI Master Circular for Mutual Funds dated May 19, 2023.

(% of Net Assets)


Instruments	Credit Rating					
	AAA	A1	AA	A	BBB	Not Applicable
<b>Debt &amp; Money Market Instruments</b>						
Certificates of Deposit(CDs)	-	0-5	-	-	-	-
Commercial Papers(CPs)		0-5	-	-	-	-
Usance Bills	-	-	-	-	-	-
Non-Convertible Debentures (NCDs)*	-	-	-	-	-	-
Government Securities**/ Treasury Bills	-	-	-	-	-	95-100
TREPS/ Reverse Repos/ Units of Debt or Liquid Mutual Funds Schemes	-	-	-	-	-	0-5

\*Includes CDs issued by All-India Financial Institutions permitted by RBI from time to time.

\*\*As defined in SID

The ratings indicated in the above table include "-" and "+". For eg. the AA rating shall also include AA- and AA+. Similarly, securities with Rating A1 shall also include A1+. For complete details, refer SID

For disclaimer refer slide 18

<p><b>HDFC Charity Fund for Cancer Cure (A Fixed Maturity Plan) is suitable for investors who are seeking*</b></p> <ul style="list-style-type: none"> <li>• Regular income over 1196 days (tenure of the Scheme)</li> <li>• Investment in debt and money market instruments and government securities</li> </ul> <p>*Investors should consult their financial advisers, if in doubt about whether the product is suitable for them. # The product labeling assigned during the NFO is based on internal assessment of the scheme characteristics or model portfolio and the same may vary post NFO when the actual investments are made.</p>		<p><b>Riskometer #</b></p> 																								
<p align="center"><b>Potential Risk Class (PRC) (Maximum risk the Scheme can take)</b></p> <table border="1"> <thead> <tr> <th></th> <th align="center"><b>Relatively Low (Class A)</b></th> <th align="center"><b>Moderate (Class B)</b></th> <th align="center"><b>Relatively High (Class C)</b></th> </tr> </thead> <tbody> <tr> <td>Credit Risk →</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Interest Rate Risk ↓</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Relatively Low (Class I)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Moderate (Class II)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Relatively High (Class III)</td> <td align="center"><b>A-III</b></td> <td></td> <td></td> </tr> </tbody> </table> <p align="center"><b>A-III - A Relatively High Interest Rate Risk and Relatively Low Credit Risk</b></p>				<b>Relatively Low (Class A)</b>	<b>Moderate (Class B)</b>	<b>Relatively High (Class C)</b>	Credit Risk →				Interest Rate Risk ↓				Relatively Low (Class I)				Moderate (Class II)				Relatively High (Class III)	<b>A-III</b>		
	<b>Relatively Low (Class A)</b>	<b>Moderate (Class B)</b>	<b>Relatively High (Class C)</b>																							
Credit Risk →																										
Interest Rate Risk ↓																										
Relatively Low (Class I)																										
Moderate (Class II)																										
Relatively High (Class III)	<b>A-III</b>																									



This presentation dated 14<sup>th</sup> July, 2023

**NSE and BSE Disclaimer:**

It is to be distinctly understood that the permission given by National Stock Exchange of India Limited (NSE)/ BSE Limited (BSE) should not in any way be deemed or construed that the Scheme Information Document (SID) has been cleared or approved by NSE/ BSE nor does it certify the correctness or completeness of any of the contents of the SID. The investors are advised to refer to the SID for the full text of the Disclaimer clause of NSE/ BSE.

**MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.**



**Thank You**